Uncategorized
This week in Drug Discovery (13 – 17 April)
News round-up for 13 – 17 April by Bruno Quinney, Content Team at DDW.
This week, breakthroughs have emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical trial set up in the UK.
The top stories:
Novel therapy could slow tumour growth
A novel cancer therapy targeting tumour acidity could boost immune response and slow cancer growth, studies show.
B7-H4-targeted ADC shows 62% response rate in ovarian cancer
The global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (Mo-Rez) has shown confirmed objective response rates (cORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent or advanced endometrial cancer (EC).
Immunopeptide could delay inflammatory arthritis, study says
Scientists investigating the naturally occurring immunopeptide PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) have shown reductions in arthritic joint swelling to a degree comparable to the current standard of care, reducing inflammatory changes that cause joint damage.
Speech overlooked as clinical marker, biotech says
SynaptixBio, which became the only company to commercialise a treatment for the rare disease H-ABC, is set to launch a study into speech as a non-invasive, digital clinical marker in neurodegenerative disease research.
Read more…
Regulatory reforms accelerate UK clinical trial set up
NHS patients are accessing groundbreaking treatments faster as the UK government fulfils its promise for a 150-day clinical trial target.
Read more…
The post This week in Drug Discovery (13 – 17 April) appeared first on Drug Discovery World (DDW).
Uncategorized
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
Roche’s multiple sclerosis pill more than doubled patients’ relapse-free interval compared with Sanofi’s marketed MS pill Aubagio, according to data presented late on Tuesday.
The drug, a BTK inhibitor called fenebrutinib, demonstrated “the lowest relapse … Read More
Uncategorized
STAT+: With successful trials, Roche takes its MS drug to regulators, but safety questions loom
The Swiss drugmaker Roche on Tuesday presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval for a medicine that it believes can cut relapse rates and slow the progressive disability the disease causes.
Now the test is whether the drug, called fenebrutinib, can win the regulatory green light.
While three late-stage trials of the drug have shown it to be effective, analysts have homed in on some potentially worrying liver safety signals, an issue that previously prompted the Food and Drug Administration to reject an MS therapy developed by Sanofi. In data released Tuesday, researchers also disclosed that there were two drug-related deaths among patients who took fenebrutinib.
The Swiss drugmaker Roche on Tuesday presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval for a medicine that it believes can cut relapse rates and slow the progressive disability the disease causes.
Now the test is whether the drug, called fenebrutinib, can win the regulatory green light.
While three late-stage trials of the drug have shown it to be effective, analysts have homed in on some potentially worrying liver safety signals, an issue that previously prompted the Food and Drug Administration to reject an MS therapy developed by Sanofi. In data released Tuesday, researchers also disclosed that there were two drug-related deaths among patients who took fenebrutinib.
Uncategorized
STAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it
SAN DIEGO — Revolution Medicines is already cooking up the next iteration of RAS inhibiting drugs.
At the American Association of Cancer Research annual meeting here, the company is the talk of the town for the clinical trial success of daraxonrasib, their next generation targeted therapy, in advanced pancreatic cancer. And while the company presented more data on that drug on Tuesday, showing promising first line and combination data on daraxonrasib, scientists also showed in another session intriguing preclinical data on a completely new compound that may represent what comes after their current lineup.
That drug, currently called RM-055, is what RevMed’s CEO Mark Goldsmith is calling an entirely “novel class of catalytic inhibitors.” These are targeted therapies that not only block the RAS signaling that drives cancer, but molecularly turn the cancer protein off.
SAN DIEGO — Revolution Medicines is already cooking up the next iteration of RAS inhibiting drugs.
At the American Association of Cancer Research annual meeting here, the company is the talk of the town for the clinical trial success of daraxonrasib, their next generation targeted therapy, in advanced pancreatic cancer. And while the company presented more data on that drug on Tuesday, showing promising first line and combination data on daraxonrasib, scientists also showed in another session intriguing preclinical data on a completely new compound that may represent what comes after their current lineup.
That drug, currently called RM-055, is what RevMed’s CEO Mark Goldsmith is calling an entirely “novel class of catalytic inhibitors.” These are targeted therapies that not only block the RAS signaling that drives cancer, but molecularly turn the cancer protein off.
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
STAT+: With successful trials, Roche takes its MS drug to regulators, but safety questions loom
STAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it
STAT+: Key GOP senators push back on Trump’s plan to cut NIH, reorganize HHS
Medicare indefinitely delays pilot plan to cover weight loss drugs
Alzheimer’s Linked to Cancer Mutations in Brain Immune Cells
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Uncategorized9 years ago
The old and New Edition cast comes together to perform
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years ago
Disney’s live-action Aladdin finally finds its stars